Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 9/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | F2RL1 | P55085 | 2/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4754403 | 0.76 | ACKR3 (0.54) | ACKR3NPC1RAB9ANAMPT | |
| SCHEMBL4754398 | 0.76 | ACKR3 (0.54) | ACKR3NPC1RAB9ANAMPT | |
| SCHEMBL4700612 | 0.73 | ACKR3 (0.48) | ACKR3KDM4EHTT | |
| SCHEMBL4700265 | 0.73 | ACKR3 (0.47) | ACKR3KDM4EHTT | |
| SCHEMBL4700267 | 0.73 | ACKR3 (0.47) | ACKR3KDM4EHTT | |
| SCHEMBL5576818 | 0.73 | ACKR3 (0.57) | ACKR3KDM4EHTT | |
| SCHEMBL14601239 | 0.73 | ACKR3 (0.57) | ACKR3KDM4EHTT | |
| SCHEMBL14624285 | 0.72 | ALDH1A1 (0.49) | ACKR3KDM4EHTTNPC1POLB | |
| SCHEMBL4700202 | 0.70 | ACKR3 (0.54) | ACKR3KDM4EHTT | |
| SCHEMBL5575509 | 0.70 | ACKR3 (0.54) | ACKR3KDM4EHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1909575-A2 | SUBSTITUTED N-CINNAMYL BENZAMIDES | ChemoCentryx Inc (US) | 2008-04-16 | — | — | EP | disclosed |
| US-20070021484-A1 | Substituted N-cinnamyl benzamides | CHEMOCENTRYX, INC. (US) | 2007-01-25 | — | — | US | disclosed |
| WO-2007002842-A2 | SUBSTITUTED N-CINNAMYL BENZAMIDES | CHEMOCENTRYX, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021484-A1 | Substituted N-cinnamyl benzamides | BRDT, BCCIP, NAT10 | ACKR3 4393/4885KDM4E 1129/4885HTT 3596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.